Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 2/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198224 | 1.00 | EPHX1 (0.46) | EPHX1ALDH1A1TDP1LAP3SPHK1 | |
| SCHEMBL251131 | 1.00 | EPHX1 (0.46) | EPHX1ALDH1A1TDP1LAP3SPHK1 | |
| SCHEMBL3377258 | 1.00 | EPHX1 (0.46) | EPHX1ALDH1A1TDP1LAP3SPHK1 | |
| SCHEMBL3379488 | 0.98 | EPHX1 (0.42) | EPHX1ALDH1A1TDP1LAP3SPHK1 | |
| SCHEMBL3382030 | 0.92 | EPHX1 (0.39) | EPHX1ALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL7878188 | 0.91 | EPHX1 (0.38) | EPHX1ALDH1A1TDP1LAP3SPHK1 | |
| SCHEMBL503739 | 0.91 | EPHX1 (0.38) | EPHX1ALDH1A1TDP1LAP3SPHK1 | |
| SCHEMBL503941 | 0.91 | EPHX1 (0.38) | EPHX1ALDH1A1TDP1LAP3SPHK1 | |
| SCHEMBL503916 | 0.91 | EPHX1 (0.38) | EPHX1ALDH1A1TDP1LAP3SPHK1 | |
| SCHEMBL7882701 | 0.91 | EPHX1 (0.38) | EPHX1ALDH1A1TDP1LAP3SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2712612-B1 | Patch preparation containing amine oxide and isopropyl myristate | NITTO DENKO CORP (JP) | 2020-03-25 | — | — | EP | claimed |
| US-9561213-B2 | Candesartan cilexetil-containing preparation | SAWAI PHARMACEUTICAL CO., LTD (JP) | 2017-02-07 | — | — | US | claimed |
| EP-2928468-A1 | CANDESARTAN CILEXETIL-CONTAINING PREPARATION | Sawai Pharmaceutical Co., Ltd. (JP) | 2015-10-14 | — | — | EP | claimed |
| US-20150265579-A1 | CANDESARTAN CILEXETIL-CONTAINING PREPARATION | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | claimed |
| WO-2014088123-A1 | CANDESARTAN CILEXETIL-CONTAINING PREPARATION | SAWAI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-12 | — | — | WO | claimed |
| EP-1163902-B1 | Transdermal preparation containing hydrophilic or salt-form drug | PACIFIC CORP (KR) | 2007-01-17 | — | — | EP | claimed |
| US-20030175314-A1 | Pharmaceutical composition for dermal application | DIDRIKSEN ERIK JOHANNES (DK) | 2003-09-18 | — | — | US | claimed |
| WO-2003043620-A1 | A PHARMACEUTICAL COMPOSITION FOR DERMAL APPLICATION | LEO PHARMA A/S (DK) | 2003-05-30 | — | — | WO | claimed |
| US-20020012695-A1 | Transdermal preparation containing hydrophilic or salt-form drug | PACIFIC CORPORATION (KR) | 2002-01-31 | — | — | US | claimed |
| EP-1163902-A2 | Transdermal preparation containing hydrophilic or salt-form drug | PACIFIC CORPORATION (KR) | 2001-12-19 | — | — | EP | claimed |
| US-20230310339-A1 | PATCH AND PRODUCTION METHOD THEREOF | KANEKA CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| CN-106456607-B | Pharmaceutical composition for topical administration | 齐阿科制药有限公司 | 2021-08-27 | — | — | CN | disclosed |
| US-20210060018-A1 | TOPICAL ADMINISTRATION OF MEK INHIBITING AGENTS FOR THE TREATMENT OF SKIN DISORDERS | DUKE UNIVERSITY | 2021-03-04 | — | — | US | disclosed |
| US-10932955-B2 | Percutaneous absorption agent delivery device and manufacturing method therefor | MEDRX CO., LTD. (JP) | 2021-03-02 | — | — | US | disclosed |
| EP-2712612-B1 | Patch preparation containing amine oxide and isopropyl myristate | NITTO DENKO CORP (JP) | 2020-03-25 | — | — | EP | disclosed |
| EP-1163902-B1 | Transdermal preparation containing hydrophilic or salt-form drug | PACIFIC CORP (KR) | 2007-01-17 | — | — | EP | disclosed |
| US-20030175314-A1 | Pharmaceutical composition for dermal application | DIDRIKSEN ERIK JOHANNES (DK) | 2003-09-18 | — | — | US | disclosed |
| WO-2003043620-A1 | A PHARMACEUTICAL COMPOSITION FOR DERMAL APPLICATION | LEO PHARMA A/S (DK) | 2003-05-30 | — | — | WO | disclosed |
| US-20020012695-A1 | Transdermal preparation containing hydrophilic or salt-form drug | PACIFIC CORPORATION (KR) | 2002-01-31 | — | — | US | disclosed |
| EP-1163902-A2 | Transdermal preparation containing hydrophilic or salt-form drug | PACIFIC CORPORATION (KR) | 2001-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030175314-A1 | Pharmaceutical composition for dermal application | TSLP, CUTA, MMP1 | EPHX1 1653/4885ALDH1A1 1898/4885TDP1 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.